FDA Grants Accelerated Approval to Datopotamab Deruxtecan-dlnk for EGFR-mutated Non-Small Cell Lung Cancer By Ogkologos - July 11, 2025 561 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the TROPION-Lung05 and TROPION-Lung01 studies Source RELATED ARTICLESMORE FROM AUTHOR FX-909 Demonstrates Acceptable Safety and Preliminary Antitumour Activity, Establishing a Proof of Concept for PPARγ Inverse Agonism in Advanced Urothelial Cancer Pimicotinib Shows Robust Antitumour Activity and Clinically Meaningful Improvements in Patients with Tenosynovial Giant Cell Tumour FDA Grants Accelerated Approval to Zongertinib for Unresectable or Metastatic Non-Squamous NSCLC MOST POPULAR Chris Pratt Partners with GreaterGood to Support Food Banks and Feed... December 18, 2020 A Combination of Atezolizumab and Enzalutamide Does Not Improve Overall Survival... January 25, 2022 News digest – dinosaur bone cancer, YouTube junk food ad ban... August 8, 2020 Development of Secondary T-Cell Cancers After the Use of CAR T-Cells... January 29, 2024 Load more HOT NEWS For Some Women with Breast Cancer, Cost Influences Decisions about Surgery More Evidence that Ruxolitinib Benefits Some Patients with Graft-Versus-Host Disease To My Fellow Nurses Cancer in My Community: Working Toward Early Diagnosis for Children With...
